A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages a..
The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine1 and reviewed in this issue of The ASCO Post, shows the efficacy of a..
The PD-L1 immune checkpoint inhibitor failed to show a superior improvement in overall survival (OS) in comparison with standard chemotherapy both in the overal..
Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Ca..
Combining cabozantinib (Cabmetyx) and atezolizumab (Tecentriq) induced durable responses in men with metastatic castration-resistant prostate cancer (CRPC) who ..
The combination of regorafenib (Stivarga) plus an oral fluoropyrimidine, TAS-102, (trifluridine/tipiracil; Lonsurf), as third-line treatment in patients with me..